Latest Conference Coverage

A single administration of LN-145 monotherapy resulted in an overall response rate of 21.4% in patients with immunotherapy pretreated metastatic non–small cell lung cancer.

The first in-human study of CAR macrophages has dosed 2 participants so far.

The BASECAMP-1 study is identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future use of these therapies.

Three patients dosed had tumors shrinkages of 18%, 21%, and 27%.

Data from the IMA203 trial were presented at the SITC 2021 annual meeting.

Thorsten Graef, MD, PhD, chief medical officer, Acepodia, discussed data on ACE1702 presented at ESMO 2021.

Overall response rate was 95%, including 75% of patients who achieved a complete response (CR) or better, with a median follow-up of 5.8 months at data cutoff.

The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.

The early-phase data readout follows news that the FDA recently approved its IND for its CAR-T candidate in multiple myeloma.

The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.

Presentations at ISTH 2021 revealed attributes most important to patients when considering gene therapies and where further research is needed.

The World Federation of Hemophilia’s registry will include long-term safety and efficacy data in people with hemophilia treated with gene therapies.

No concerning effects to liver health were observed in the phase 1/2a study.

Phase 3 studies are continuing in the enhanced Padua FIX variant AMT-061 for hemophilia B.

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.

The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

Stephen J. Schuster, MD, discussed tisagenlecleucel's efficacy and safety over other available treatments for relapsed/refractory FL.

A drop in endogenous Factor VIII expression was observed from treatment to 5-year follow-up despite continued demonstration of efficacy.

Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.

The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.

Findings from an ongoing phase 1 trial were presented at the 2021 ASGCT meeting.

The founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.

Over 90% participants had an annualized bleeding rate of 0 or a lower bleed rate than baseline after week 4 after treatment.

Early safety and efficacy data support the use of natural killer T (NKT) cells in patients with stage IV relapsed/refractory neuroblastoma.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed strategies to manage AEs associated with CAR T therapy.

The founder and chief executive officer of SQZ Biotech discussed the development and advantages of their proprietary Cell Squeeze technology in creating cell therapies.

The CEO of Avamab Pharma discussed how funding and research changes directions.

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.